2028 Forecast in Adult Cardiac Surgery

Unless otherwise noted, speakers have nothing to disclose.

Moderators

Gorav Ailawadi, MD, MBA
Disclosure: Edwards Lifesciences, Medtronic, AtriCure, Abbott, CryoLife, Johnson and Johnson, ClearFlow: Advisory Board (Ongoing), Consultant (Ongoing)

Tsuyoshi Kaneko, MD
Disclosure: Medtronic: Consultant (Ongoing), Speaker (Ongoing); Abbott: Consultant (Ongoing); Edwards Life Science: Advisory Board (Ongoing), Consultant (Ongoing), Speaker (Ongoing)

Presentations

  1. The View: Landscape of Adult Cardiac Surgery in 2028
    Joseph Bavaria, MD, FACS, FRCS 
    Disclosure: Medtronic: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Abbott/St. Jude Medical: DSMB Chair (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Edwards Life Science: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Terumo Aortic: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); W. L. Gore & Associates: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
     
  2. Valve Surgery in 2028: From Synthetic Valve to Transcatheter Technology
    Isaac George, MD
    Disclosure: Medtronic: Advisory Board (Ongoing); Abbvie: Advisory Board (Ongoing), Consultant (Ongoing); AtriCure: Consultant (Ongoing), Speaker (Ongoing); Cardiomech: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); durvena: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Edwards Life Science: Advisory Board (Ongoing); Foldax, Inc: Advisory Board (Ongoing); Johnson and Johnson: Consultant (Ongoing); MitreMedical: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); MITrx: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); neosurgery: Advisory Board (Ongoing), Consultant (Ongoing); neptune medical: Consultant (Ongoing); trisol medical: Advisory Board (Ongoing); valcare medical: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); VDyne: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Zimmer Biomet: Advisory Board (Ongoing), Consultant (Ongoing)
     
  3. Aortic Surgery in 2028: Arch and Ascending TEVAR
    G. Chad Hughes, IV, MD
     
  4. New Technology in Heart Failure in 2028: Percutaneous and Future Assist Devices
    Marisa Cevasco, MD
     
  5. Coronary Surgery in 2028: Robotics, Hybrid, and Beyond
    Husam H. Balkhy, MD
    Disclosure(s): Edwards: Consultant (Ongoing), proctor (Ongoing); Intuitive: proctor (Ongoing), Speaker (Ongoing)
     
  6. Panel Discussion
     
  7. Resident Education in 2028: Evolution or Specialization
    David A. Fullerton, MD
     
  8. Panel Discussion
Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation
Activity opens: 
02/01/2023
Activity expires: 
02/01/2026
Cost:
$0.00
Rating: 
0

Available Credit

  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Unless otherwise noted, speakers have nothing to disclose.

Moderators

Gorav Ailawadi, MD, MBA
Disclosure: Edwards Lifesciences, Medtronic, AtriCure, Abbott, CryoLife, Johnson and Johnson, ClearFlow: Advisory Board (Ongoing), Consultant (Ongoing)

Tsuyoshi Kaneko, MD
Disclosure: Medtronic: Consultant (Ongoing), Speaker (Ongoing); Abbott: Consultant (Ongoing); Edwards Life Science: Advisory Board (Ongoing), Consultant (Ongoing), Speaker (Ongoing)

Presentations

  1. The View: Landscape of Adult Cardiac Surgery in 2028
    Joseph Bavaria, MD, FACS, FRCS 
    Disclosure: Medtronic: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Abbott/St. Jude Medical: DSMB Chair (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Edwards Life Science: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Terumo Aortic: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); W. L. Gore & Associates: Consultant (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)
     
  2. Valve Surgery in 2028: From Synthetic Valve to Transcatheter Technology
    Isaac George, MD
    Disclosure: Medtronic: Advisory Board (Ongoing); Abbvie: Advisory Board (Ongoing), Consultant (Ongoing); AtriCure: Consultant (Ongoing), Speaker (Ongoing); Cardiomech: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); durvena: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Edwards Life Science: Advisory Board (Ongoing); Foldax, Inc: Advisory Board (Ongoing); Johnson and Johnson: Consultant (Ongoing); MitreMedical: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); MITrx: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); neosurgery: Advisory Board (Ongoing), Consultant (Ongoing); neptune medical: Consultant (Ongoing); trisol medical: Advisory Board (Ongoing); valcare medical: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); VDyne: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Zimmer Biomet: Advisory Board (Ongoing), Consultant (Ongoing)
     
  3. Aortic Surgery in 2028: Arch and Ascending TEVAR
    G. Chad Hughes, IV, MD
     
  4. New Technology in Heart Failure in 2028: Percutaneous and Future Assist Devices
    Marisa Cevasco, MD
     
  5. Coronary Surgery in 2028: Robotics, Hybrid, and Beyond
    Husam H. Balkhy, MD
    Disclosure(s): Edwards: Consultant (Ongoing), proctor (Ongoing); Intuitive: proctor (Ongoing), Speaker (Ongoing)
     
  6. Panel Discussion
     
  7. Resident Education in 2028: Evolution or Specialization
    David A. Fullerton, MD
     
  8. Panel Discussion